Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts

Table 1 Patients’ data

ID	Tumor	Age^a	BMI	Ca12–5	HE4	Stage
26	HGSOC	50′s–60′s	18.7	979	999	IIIA1 (i)
09	HGSOC	40′s–50′s	22.3	541	485	IIIB
34	HGSOC	50′s–60′s	25.0	1616	196	IIIB
28	HGSOC	50′s–60′s	33.0	1389	388	IIIC
30	HGSOC	50′s–60′s	25.4	867	979	IVB
46	HGSOC	50′s–60′s	32.6	807	220	IVB
65	HGSOC	60′s–70′s	36.4	1551	832	IVB
23	HGSOC	70′s–80′s	27.3	416	1500	≥ IIIC^b
39	HGSOC	70′s–80′s	18.1	680	766	IVB
		md 58 av 59	md 25.4 av 27.0	md 867 av 983	md 766 av 707
55	Cystadenoma	50′s–60′s	24.7	76	53
17	Cystadenoma	40′s–50′s	23.9	24	164
61	Cystadenoma	40′s–50′s	26.6	35	34
32	Tecoma	70′s–80′s	25.1	173	NA
35	Fibroma	50′s–60′s	37.2	69	NA
63	Fibroma	80′s–90′s	26.6	126	56
36	Teratoma	40′s–50′s	NA	152	46
		md 53 av 56	md 25.8 av 27.3	md 65 av 70	md 53 av 68

The data of the patients gathered at the stage of diagnosis and after the surgery
^aThe age of the participants is presented as a range in order to protect their anonymity, BMI, body mass index, Ca12-5, plasma Ca12-5 antigen value; HE4, plasma human epididymal antigen 4 value; Stage, stage of the ovarian cancer according to FIGO 2016 guidelines, HGSOC, high-grade serous ovarian cancer; ^b Inoperable patient, no thorough staging operation. md, median; av, average; NA, Not available

ISSN: 1756-0500